The FDA has requested that Congress approve $22 million in new user fees to be paid by medical device and drug companies whose facilities require reinspection by the agency. Although the policy might encourage companies to clean up FDA violations in their plants more quickly, the reinspection fees could mean significant costs for the companies.

Related Summaries